CAJ | 학술논문

泊马度胺是新一代的免疫调节剂(IMiD),因其在针对难治复发性多发性骨髓瘤(RRMM)的临床试验中显示出了令人鼓舞的疗效,被美国FDA批准用于至少经过两种治疗无效(包括来那度胺和硼替佐米)和最后一次治疗后60 d内病情恶化的患者.文章主要对泊马度胺在RRMM治疗中的研究进展进行综述.
박마도알시신일대적면역조절제(IMiD),인기재침대난치복발성다발성골수류(RRMM)적림상시험중현시출료령인고무적료효,피미국FDA비준용우지소경과량충치료무효(포괄래나도알화붕체좌미)화최후일차치료후60 d내병정악화적환자.문장주요대박마도알재RRMM치료중적연구진전진행종술.
Pomalidomide,which represents a new generation of immunomodulatory drugs (IMiD),has brought a major shift in therapeutic paradigm in treating relapsed and refractory multiple myeloma (RRMM).Considering its encouraging effectiveness,the U.S.Food and Drug Administration (FDA) approved its usage to treat patients who fail to respond to at least two prior therapies,including lenalidomide and bortezomib,and whose disease progressed within 60 days of the last treatment.This review summarizes the mechanisms of action and clinical activity of pomalidomide in treating RRMM.